id:"swepub:oai:lup.lub.lu.se:0f3a3908-b3cb-40b4-89fd-c6d7872c43e0"
Search: id:"swepub:oai:lup.lub.lu.se:0f3a3908-b3cb-40b4-89fd-c6d7872c43e0" > ATOR-1017 (evunzeki...
- 1 of 1
- Previous record
- Next record
- To hitlist
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1
-
- Enell Smith, Karin (author)
- Alligator Biosciences AB
-
- Fritzell, Sara (author)
- Alligator Biosciences AB
-
- Nilsson, Anneli (author)
- Alligator Biosciences AB
- show more...
- Barchan, Karin (author)
- Rosén, Anna (author)
- Schultz, Lena (author)
- Rose, Nadia (author)
- show less...
- (creator_code:org_t)
- 2023
- 2023
- English 15 s.
- In: Cancer Immunology, Immunotherapy. - 0340-7004. ; 72:12, s. 4145-4159
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Background: 4-1BB (CD137) is a co-stimulatory receptor highly expressed on tumor reactive effector T cells and NK cells, which upon stimulation prolongs persistence of tumor reactive effector T and NK cells within the tumor and induces long-lived memory T cells. 4-1BB agonistic antibodies have been shown to induce strong anti-tumor effects that synergize with immune checkpoint inhibitors. The first generation of 4-1BB agonists was, however, hampered by dose-limiting toxicities resulting in suboptimal dose levels or poor agonistic activity. Methods: ATOR-1017 (evunzekibart), a second-generation Fc-gamma receptor conditional 4-1BB agonist in IgG4 format, was designed to overcome the limitations of the first generation of 4-1BB agonists, providing strong agonistic effect while minimizing systemic immune activation and risk of hepatoxicity. The epitope of ATOR-1017 was determined by X-ray crystallography, and the functional activity was assessed in vitro and in vivo as monotherapy or in combination with anti-PD1. Results: ATOR-1017 binds to a unique epitope on 4-1BB enabling ATOR-1017 to activate T cells, including cells with an exhausted phenotype, and NK cells, in a cross-linking dependent, FcγR-conditional, manner. This translated into a tumor-directed and potent anti-tumor therapeutic effect in vivo, which was further enhanced with anti-PD-1 treatment. Conclusions: These preclinical data demonstrate a strong safety profile of ATOR-1017, together with its potent therapeutic effect as monotherapy and in combination with anti-PD1, supporting further clinical development of ATOR-1017.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- 4-1BB
- Antibody
- CD137
- Immunotherapy
- PD-1
- T cell activation
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
- Cancer Immunology, Immunotherapy (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Enell Smith, Kar ...
- Fritzell, Sara
- Nilsson, Anneli
- Barchan, Karin
- Rosén, Anna
- Schultz, Lena
- show more...
- Varas, Laura
- Säll, Anna
- Rose, Nadia
- Håkansson, Maria
- von Schantz, Lau ...
- Ellmark, Peter
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
- Articles in the publication
- Cancer Immunolog ...
- By the university
- Lund University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
